Leaflet:information for the user
Fucibet 20 mg/g + 1 mg/g cream
fusidic acid and betamethasone
Read the entire leaflet carefully before starting to use this medicine, as it contains important information for you.
Contents of the leaflet
Fucibet cream combines the antibacterial action of fusidic acid (antibiotic) with the anti-inflammatory effect of a corticosteroid, betamethasone (as valerate).
It is used for the local treatment, in adults and children, of eczematous dermatitis, such as: atopic eczema, infantile eczema, discoid eczema (in the form of circular patches), stasis eczema (eczema on the legs that appears in some patients with hypertension), contact eczema, and seborrheic eczema, in which a secondary bacterial infection has been confirmed or is suspected.
You should consult a doctor if it worsens or does not improve after 14 days.
Do not use Fucibet:
Fucibet contains a corticosteroid, betamethasone (as valerate), and should not be used in the following situations:
Warnings and precautions
Consult your doctor or pharmacist before starting to use Fucibet.
Children and adolescents
Fucibet should be used with caution in children and adolescents, as they may be more susceptible to developing Cushing's syndrome (characterized by a rounded face, fat accumulation, delayed healing, fatigue...) due to increased absorption through the skin. Prolonged treatments, application of large amounts of medicine, and occlusion of the affected area should be avoided, see section 3.
Using Fucibet with other medicines
Inform your doctor or pharmacist if you are using or have recently used any other medicine. The interaction with other systemically administered medicines is considered minimal.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
This medicine should not be used during pregnancy, as your doctor will assess the benefit of treatment for the mother and the risk to the child.
This medicine can be used during breastfeeding, but it is recommended to avoid applying the medicine to the breasts.
Driving and using machines
The influence of this medicine on the ability to drive and use machines is nil or insignificant.
Fucibet contains cetyl alcohol and chlorocresol
This medicine may cause local skin reactions (such as contact dermatitis) because it contains cetyl alcohol.
This medicine may cause allergic reactions because it contains chlorocresol.
Follow the instructions for administration of this medicine indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Administration: cutaneous route.
The recommended dose for adults and pediatric population (children and adolescents) is:
Apply a thin layer of cream carefully to the affected area, two or three times a day, for a maximum of 14 days.
In adults, the treatment of more resistant lesions may be reinforced by applying this medicine with an occlusive dressing. In these cases, nocturnal occlusion is generally considered an adequate option.
In children and adolescents, no occlusive dressing should be applied, nor large amounts of product to cover the area to be treated.
After applying this medicine, wash your hands carefully, unless your hands are the area to be treated.
If you use more Fucibet than you should
If you have applied more cream than you should, consult your doctor or pharmacist.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount ingested.
If you forget to use Fucibet
In case you forget to apply the cream at the scheduled time, apply it as soon as possible and continue according to the usual schedule.
If you interrupt treatment with Fucibet
If you forget to apply this medicine, do so as soon as you remember. Perform the next application according to the usual schedule.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, Fucibet can cause side effects, although not everyone gets them.
Side effects uncommon(may affect up to 1 in 100 people):
Side effects rare(may affect up to 1 in 1,000 people):
Side effects with an unknown frequency (cannot be estimated from the available data):
Other side effects caused by prolonged treatment with potent corticosteroids may include:
Reporting side effects:
If you experience any side effects, consult your doctor or pharmacist, even if they are possible side effects not listed in this leaflet. You can also report them directly through the Spanish Medicines and Health Products Agency's pharmacovigilance system: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the carton after CAD. The expiration date is the last day of the month indicated.
Discard the tube 3 months after the first opening. Indicate the opening date in the box on the outer packaging.
Do not store above 30°C. Store in the original packaging.
Medicines should not be disposed of via wastewater or household waste. Deposit the containers and medicines you no longer need at the pharmacy's SIGRE point. If in doubt, ask your pharmacist how to dispose of the containers and medicines you no longer need. This will help protect the environment.
Composition ofFucibet
Each gram of cream contains 20 mg of fusidic acid and 1 mg of betamethasone (as valerate).
Appearance of the productand package contents
Fucibet is a white cream.
Each carton contains an aluminum tube with a polyethylene screw cap with 30 or 60 grams of cream.
Only some package sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder
LEO Pharma Laboratories, S.A.
Via Laietana 33, 7th floor
08003 Barcelona
Spain
Manufacturer
LEO Laboratories Limited
Cashel Road
Dublin 12 (Ireland).
LEO Pharma Manufacturing Italy S.r.l.
Via E. Schering 21
20054 Segrate (MI)
Italy.
Date of the last revision of this leaflet August 2018
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es